R&D News | pharmaphorum

News

Celgene gets fast FDA review of Revlimid combo in lymphoma

Celgene is closing in on yet another new indication for its blood cancer blockbuster Revlimid, with the FDA starting a priority review of the drug in combination with Roche’s Rituxan.

News

Signing paperwork with a fountain paperwork. The image has added grain and styling.

M&A flurry continues with $21bn Danaher bid for GE unit

GE Healthcare was supposed to be heading for an initial public offering (IPO) this year, but that looks less likely after a $21.4 billion buyout offer for its biopharma unit from medtech co

News

Sanofi/Regeneron’s Dupixent shows more promise in nasal poly...

Sanofi and Regeneron’s attempts to make Dupixent into a blockbuster franchise have been boosted with more strong phase 3 results in patients with chronic rhinosinusitis with nasal polyps (CRSwNP

News

Novartis licenses lipoprotein-lowering CVD drug

Excited by strong phase II data, Novartis is exercising its option to license Akcea Therapeutics’ TQJ230, a treatment to reduce the risk of cardiovascular disease in people living with elev

News

AbbVie upscales Voyager alliance with new target, more cash

AbbVie has extended its collaboration with gene therapy specialist Voyager Therapeutics, adding a new programme in Parkinson’s disease and another $1.5 billion in potential fees.

News

Cell therapy produces encouraging first results in eye trial

UK-based biotech ReNeuron has announced encouraging results from an early stage trial of its cell therapy for the rare blindness-causing disease, retinitis pigmentosa (RP).

Celgene gets fast FDA review of Revlimid combo in lymphoma

M&A flurry continues with $21bn Danaher bid for GE unit

Sanofi/Regeneron’s Dupixent shows more promise in nasal poly...

Novartis licenses lipoprotein-lowering CVD drug

AbbVie upscales Voyager alliance with new target, more cash

Cell therapy produces encouraging first results in eye trial

Bayer plans filings for cardiac amyloidosis imaging agent

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks